EventsThursday, April 07, 2016 02:00 PM - 05:00 PM
Insights from a Staff Scientist who has held Industry and Government Positions
Brought to you by the Department of Animal Science and the BEST Program: Mary Ellen Urick, NIH National Human Genome Research Institute
2:00 PM Interactive Session: A Tale of Two Positions: Insights from a Staff Scientist who has held Industry and Government Positions
Please join us for a candid discussion with Mary Ellen Urick, a Cornell alumna who spent two years as a staff scientist at Thermo Fisher Scientific (formerly Life Technologies) and who is now a staff scientist at the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). This session will provide opportunities to:
- Acquire answers to your questions regarding industry and government post-PhD positions from a scientist who has held both.
- Discuss the skills needed to obtain and maintain a staff scientist position in industry and the government.
- Network with a Cornell alumna and your colleagues
See flyer here.
4:00 PM Animal Science Seminar: Uncovering Somatic Mutations in Clinically Aggressive Endometrial Carcinoma
In this seminar, Dr. Urick will present her previous and current work at the National Human Genome Research Institute (NHGRI), including the novel discovery of frequent functional mutations in the regulatory subunit of PI3K and whole exome sequencing of serous endometrial cancer.
Flyer about the seminar available here.
Brief biography: Mary Ellen Urick is a staff scientist at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) in Daphne Bell’s lab, which specializes in identification of genomic aberrations that cause clinically aggressive forms of endometrial cancer. In her current role, she is studying the functional relevance of genomic aberrations identified in these deadly diseases.
Prior to obtaining a staff scientist position at NHGRI, she earned her doctorate from Cornell University in 2008 by demonstrating the role of the cyclooxygenase enzymes in the hen model of human ovarian cancer. She subsequently completed postdoctoral studies at the National Cancer Institute (NCI) and NHGRI. During her time at the NCI, Dr. Urick studied the clinical significance of pharmaceutical agents as radiosensitizers. While at NHGRI, she studied the functional relevance of genetic mutations present in endometrial cancer. Her work was the first to show that somatic mutations in PIK3R1 are common in endometrial cancers. Following her postdoctoral studies, Dr. Urick spent 2 years in an industry setting providing oncology genomics solutions including but not limited to identification/validation of novel drug targets, selection of cohorts for treatment stratification, and identification of potentially clinically relevant biomarkers for Thermo Fisher Scientific (formerly Life Technologies) before returning to NHGRI for a staff scientist position.
2 pm BEST interactive session
4 pm Seminar
Reception to follow